Literature DB >> 608810

Preparation of a biologically stable and immunogenically competent astatinated protein.

A M Friedman, M R Zalutsky, W Wung, F Buckingham, G H Scherr, B Wainer, R L Hunter, E H Appelman, R M Rothberg, F W Fitch, F P Stuart, S J Simonian.   

Abstract

Mesh：

Substances：

Year:  1977        PMID： 608810     DOI： 10.1016/0047-0740(77)90146-2

Source DB:  PubMed          Journal:  Int J Nucl Med Biol        ISSN： 0047-0740


× No keyword cloud information.
  6 in total

Review 1.  Astatine-211: production and availability.

Authors:  Michael R Zalutsky; Marek Pruszynski
Journal:  Curr Radiopharm       Date:  2011-07

2.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

Authors:  M R Zalutsky; P K Garg; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

3.  Astatine Radiopharmaceuticals: Prospects and Problems.

Authors:  Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Curr Radiopharm       Date:  2008-09-01

Review 4.  Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted α-particle therapy.

Authors:  François Guérard; Jean-François Gestin; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2012-10-17       Impact factor: 3.099

5.  Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

Authors:  Marek Pruszyński; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Bioconjug Chem       Date:  2008-03-14       Impact factor: 4.774

Review 6.  Production, purification and availability of 211At: Near term steps towards global access.

Authors:  Yutian Feng; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-06-10       Impact factor: 2.947
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.